Exact Mass: 552.2604
Exact Mass Matches: 552.2604
Found 206 metabolites which its exact mass value is equals to given mass value 552.2604
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
PA(2:0/PGF1alpha)
PA(2:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF1alpha/2:0)
PA(PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/2:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(5R*,7S*,8S*,9S*,10R*)-1-beta-D-glucopyranosyl-7alpha-acetoxycleroda-3,13-dien-16,15-olide-18-oate
(5R*,7S*,8S*,9S*,10R*)-1-beta-D-glucopyranosyl-7alpha-acetoxycleroda-3,13-dien-15,16-olide-18-oate
Glu Tyr Asn Lys
Asp Lys Gln Tyr
Asp Lys Tyr Gln
Asp Gln Lys Tyr
Asp Gln Tyr Lys
Asp Tyr Lys Gln
Asp Tyr Gln Lys
Glu Lys Asn Tyr
Glu Lys Tyr Asn
Glu Asn Lys Tyr
Glu Asn Tyr Lys
Glu Tyr Lys Asn
Gly Lys Trp Tyr
Gly Lys Tyr Trp
Gly Trp Lys Tyr
Gly Trp Tyr Lys
Gly Tyr Lys Trp
Gly Tyr Trp Lys
Lys Asp Gln Tyr
Lys Asp Tyr Gln
Lys Glu Asn Tyr
Lys Glu Tyr Asn
Lys Gly Trp Tyr
Lys Gly Tyr Trp
Lys Asn Glu Tyr
Lys Asn Tyr Glu
Lys Gln Asp Tyr
Lys Gln Tyr Asp
Lys Trp Gly Tyr
Lys Trp Tyr Gly
Lys Tyr Asp Gln
Lys Tyr Glu Asn
Lys Tyr Gly Trp
Lys Tyr Asn Glu
Lys Tyr Gln Asp
Lys Tyr Trp Gly
Asn Glu Lys Tyr
Asn Glu Tyr Lys
Asn Lys Glu Tyr
Asn Lys Tyr Glu
Asn Arg Thr Tyr
Asn Arg Tyr Thr
Asn Thr Arg Tyr
Asn Thr Tyr Arg
Asn Tyr Glu Lys
Asn Tyr Lys Glu
Asn Tyr Arg Thr
Asn Tyr Thr Arg
Gln Asp Lys Tyr
Gln Asp Tyr Lys
Gln Lys Asp Tyr
Gln Lys Tyr Asp
Gln Arg Ser Tyr
Gln Arg Tyr Ser
Gln Ser Arg Tyr
Gln Ser Tyr Arg
Gln Tyr Asp Lys
Gln Tyr Lys Asp
Gln Tyr Arg Ser
Gln Tyr Ser Arg
Arg Asn Thr Tyr
Arg Asn Tyr Thr
Arg Gln Ser Tyr
Arg Gln Tyr Ser
Arg Ser Gln Tyr
Arg Ser Tyr Gln
Arg Thr Asn Tyr
Arg Thr Tyr Asn
Arg Tyr Asn Thr
Arg Tyr Gln Ser
Arg Tyr Ser Gln
Arg Tyr Thr Asn
Ser Gln Arg Tyr
Ser Gln Tyr Arg
Ser Arg Gln Tyr
Ser Arg Tyr Gln
Ser Tyr Gln Arg
Ser Tyr Arg Gln
Thr Asn Arg Tyr
Thr Asn Tyr Arg
Thr Arg Asn Tyr
Thr Arg Tyr Asn
Thr Tyr Asn Arg
Thr Tyr Arg Asn
Trp Gly Lys Tyr
Trp Gly Tyr Lys
Trp Lys Gly Tyr
Trp Lys Tyr Gly
Trp Tyr Gly Lys
Trp Tyr Lys Gly
Tyr Asp Lys Gln
Tyr Asp Gln Lys
Tyr Glu Lys Asn
Tyr Glu Asn Lys
Tyr Gly Lys Trp
Tyr Gly Trp Lys
Tyr Lys Asp Gln
Tyr Lys Glu Asn
Tyr Lys Gly Trp
Tyr Lys Asn Glu
Tyr Lys Gln Asp
Tyr Lys Trp Gly
Tyr Asn Glu Lys
Tyr Asn Lys Glu
Tyr Asn Arg Thr
Tyr Asn Thr Arg
Tyr Gln Asp Lys
Tyr Gln Lys Asp
Tyr Gln Arg Ser
Tyr Gln Ser Arg
Tyr Arg Asn Thr
Tyr Arg Gln Ser
Tyr Arg Ser Gln
Tyr Arg Thr Asn
Tyr Ser Gln Arg
Tyr Ser Arg Gln
Tyr Thr Asn Arg
Tyr Thr Arg Asn
Tyr Trp Gly Lys
Tyr Trp Lys Gly
Emetine hydrochloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D005765 - Gastrointestinal Agents > D002400 - Cathartics D005765 - Gastrointestinal Agents > D004639 - Emetics D002491 - Central Nervous System Agents C784 - Protein Synthesis Inhibitor
(2R,3S,4S,5S)-5-HYDROXY-2,3,4-TRIS(PHENYLMETHOXY)-5-[(PHENYLMETHOXY)METHYL]-CYCLOHEXANONE
1,1-Hexadecane-1,16-diylbis(1-methylpyrrolidinium) dibromide
3-(1,3-benzodioxol-5-yl)-1-[[(2R,3S)-8-(3-hydroxyhex-1-ynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
N-[(2S,3S)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
N-[(2R,3S)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
N-[(2R,3R)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
N-[(2S,3S)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
(6-{[4-(1,4-dihydroxy-2,2,6-trimethylcyclohexyl)but-3-en-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate
(1r,2s,3e,5s,7s,8e,10r,13s)-5,9,10-tris(acetyloxy)-2,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-13-yl acetate
(1r,2r,3s,4r,5r,7s,8s,9s,12z,14s,17r)-7,9-bis(acetyloxy)-2,4-dihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-5-yl butanoate
ethyl 4-[(1s,7s,13r,15r)-3-hydroxy-5-oxo-7-phenyl-13-[(1e)-2-phenylethenyl]-8,14-dioxatetracyclo[11.3.1.0²,¹¹.0⁴,⁹]heptadeca-2,4(9),10-trien-15-yl]butanoate
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 7-(acetyloxy)-5,6,8a-trimethyl-5-[2-(2-oxo-5h-furan-3-yl)ethyl]-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylate
17-hydroxy-12-methyl-7-oxo-17-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-8-oxapentacyclo[14.2.1.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-5-en-18-yl acetate
(1s,2s,3e,5r,7s,8z,10r,13s)-2,9,10-tris(acetyloxy)-5,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethylbicyclo[9.3.1]pentadeca-3,8,11-trien-13-yl acetate
4,15-dimethoxy-2,6,14,17-tetramethyl-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-4,14-diene-3,16-dione
(1s,2r,3s,4s,5r,7s,8s,9r,12z,14s,17r)-2,7-bis(acetyloxy)-4,5-dihydroxy-4,8,12,17-tetramethyl-16-oxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadec-12-en-9-yl butanoate
(2r,3z,5s,7s,8e,10s,11r,13s)-2,3,10-tris(acetyloxy)-7,13-dihydroxy-8-(hydroxymethyl)-4,14,15,15-tetramethylbicyclo[9.3.1]pentadeca-1(14),3,8-trien-5-yl acetate
13-deacetylcanadensene
{"Ingredient_id": "HBIN001161","Ingredient_name": "13-deacetylcanadensene","Alias": "NA","Ingredient_formula": "C28H40O11","Ingredient_Smile": "CC1=C2C(C(=C(C(CC(C(=CC(C(C2(C)C)CC1O)OC(=O)C)CO)O)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4734","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-deacetyltaxachitriene b
{"Ingredient_id": "HBIN011505","Ingredient_name": "5-deacetyltaxachitriene b","Alias": "NA","Ingredient_formula": "C28H40O11","Ingredient_Smile": "CC1=C2C(C(=C(C(CC(C(=CC(C(C2(C)C)CC1OC(=O)C)O)CO)O)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "552.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4776","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101702748","DrugBank_id": "NA"}
7-Deacetylcanadensene
{"Ingredient_id": "HBIN013143","Ingredient_name": "7-Deacetylcanadensene","Alias": "[(1R,2S,3E,5S,7S,8Z,10R,13S)-2,9,10-triacetoxy-5,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-bicyclo[9.3.1]pentadeca-3,8,11-trienyl] acetate; [(1R,2S,3E,5S,7S,8Z,10R,13S)-2,9,10-triacetyloxy-5,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-bicyclo[9.3.1]pentadeca-3,8,11-trienyl] ethanoate; acetic acid [(1R,2S,3E,5S,7S,8Z,10R,13S)-2,9,10-triacetoxy-5,7-dihydroxy-8,12,15,15-tetramethyl-4-methylol-13-bicyclo[9.3.1]pentadeca-3,8,11-trienyl] ester; acetic acid [(1R,2S,3E,5S,7S,8Z,10R,13S)-2,9,10-triacetoxy-5,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-bicyclo[9.3.1]pentadeca-3,8,11-trienyl] ester; 7-deacetylcanadensene; [(1R,2S,3E,5S,7S,8Z,10R,13S)-2,9,10-triacetyloxy-5,7-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-bicyclo[9.3.1]pentadeca-3,8,11-trienyl] acetate","Ingredient_formula": "C28H40O11","Ingredient_Smile": "CC1=C(C(C2=C(C(CC(C2(C)C)C(C=C(C(CC1O)O)CO)OC(=O)C)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "552.61","OB_score": "7.53251491","CAS_id": "222404-07-1","SymMap_id": "SMIT01201","TCMID_id": "4733","TCMSP_id": "MOL011386","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}